Esketamine nasal spray shows greater improvement in health-related quality of life over 32 weeks versus quetiapine extended release in patients with treatment resistant depression

AH Young; BT Baune; N Cardoner; R Frey; T Ito; Y Kambarov; A Lacerda; B Rive; C von Holt; AJ Oliveira-Maia

doi:10.1192/j.eurpsy.2024.749

Esketamine nasal spray shows greater improvement in health-related quality of life over 32 weeks versus quetiapine extended release in patients with treatment resistant depression

AH Young, BT Baune, N Cardoner, R Frey, T Ito, Y Kambarov, A Lacerda, B Rive, C von Holt, AJ Oliveira-Maia

NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S363-S365
Number of pages	3
Journal	European Psychiatry
Volume	67
DOIs	https://doi.org/10.1192/j.eurpsy.2024.749
Publication status	Published - Apr 2024

Access to Document

10.1192/j.eurpsy.2024.749

Cite this

Young, AH., Baune, BT., Cardoner, N., Frey, R., Ito, T., Kambarov, Y., Lacerda, A., Rive, B., von Holt, C., & Oliveira-Maia, AJ. (2024). Esketamine nasal spray shows greater improvement in health-related quality of life over 32 weeks versus quetiapine extended release in patients with treatment resistant depression. European Psychiatry, 67, S363-S365. https://doi.org/10.1192/j.eurpsy.2024.749

@article{ea0ad74161ab4c35bc5f0b38ee2afe3e,

title = "Esketamine nasal spray shows greater improvement in health-related quality of life over 32 weeks versus quetiapine extended release in patients with treatment resistant depression",

author = "AH Young and BT Baune and N Cardoner and R Frey and T Ito and Y Kambarov and A Lacerda and B Rive and {von Holt}, C and AJ Oliveira-Maia",

year = "2024",

month = apr,

doi = "10.1192/j.eurpsy.2024.749",

language = "English",

volume = "67",

pages = "S363--S365",

journal = "European Psychiatry",

issn = "0924-9338",

publisher = "European Psychiatric Association | Cambridge University Press",

}

Young, AH, Baune, BT, Cardoner, N, Frey, R, Ito, T, Kambarov, Y, Lacerda, A, Rive, B, von Holt, C & Oliveira-Maia, AJ 2024, 'Esketamine nasal spray shows greater improvement in health-related quality of life over 32 weeks versus quetiapine extended release in patients with treatment resistant depression', European Psychiatry, vol. 67, pp. S363-S365. https://doi.org/10.1192/j.eurpsy.2024.749

TY - JOUR

T1 - Esketamine nasal spray shows greater improvement in health-related quality of life over 32 weeks versus quetiapine extended release in patients with treatment resistant depression

AU - Young, AH

AU - Baune, BT

AU - Cardoner, N

AU - Frey, R

AU - Ito, T

AU - Kambarov, Y

AU - Lacerda, A

AU - Rive, B

AU - von Holt, C

AU - Oliveira-Maia, AJ

PY - 2024/4

Y1 - 2024/4

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=nova_api&SrcAuth=WosAPI&KeyUT=WOS:001310523501350&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1192/j.eurpsy.2024.749

DO - 10.1192/j.eurpsy.2024.749

M3 - Meeting Abstract

SN - 0924-9338

VL - 67

SP - S363-S365

JO - European Psychiatry

JF - European Psychiatry

ER -

Esketamine nasal spray shows greater improvement in health-related quality of life over 32 weeks versus quetiapine extended release in patients with treatment resistant depression

Access to Document

Other files and links

Cite this